Mammogen Raises $30M for Blood-Based Breast Cancer Detection Assay
5 June 2026
BioWorld recently featured Mammogen following the company’s Series A financing of up to $30 million to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform.
The article highlights genTRU-breast™, Mammogen’s blood-based assay designed to detect molecular signatures associated with breast cancer through a simple blood draw, and the company’s continued progress toward advancing earlier and more personalized approaches to breast cancer detection.
NBC 10 News featured Mammogen CEO Elizabeth Cormier-May in its coverage of the evolving landscape of blood-based cancer detection and an upcoming FDA advisory committee review of GRAIL’s Galleri test. Cormier-May shared her perspective on the significance of liquid biopsy technology and discussed how Mammogen’s approach differs by focusing specifically on earlier breast cancer detection. The story also highlights Mammogen’s blood-based test and its potential role in supporting women who may need additional testing following their annual mammogram. Read the full article on NBC 10 News →
The Scientist | Elizabeth Cormier-May In this contributed article for The Scientist, Mammogen Co-Founder and CEO Elizabeth Cormier-May explores why RNA may represent the next frontier in molecular diagnostics. The article examines how RNA can provide a dynamic view of what is happening biologically in real time, and why that information may be particularly valuable in early cancer detection. Cormier-May also discusses the importance of moving beyond simply detecting disease earlier toward generating insights that can meaningfully inform clinical decisions and patient care. Read the full article on The Scientist →
RNA opens a window into biology in motion, shifting molecular diagnostics from measuring more biology to finding the right biology in time to change patient care.